CLAIMS

1. Semaglutide for use in treatment of obesity or overweight of a human subject in need thereof, wherein said semaglutide is to be administered subcutaneously to said subject in an amount of about 7.2 mg per week, wherein said semaglutide is not to be co-administered with cyclodextrin.

2. The semaglutide for use according to claim 1, wherein for said treatment of overweight said subject may have at least one weight-related co-morbidity.

3. The semaglutide for use according to any one of the preceding claims, wherein at least 25% of subjects obtain a body weight reduction of at least 25% with said about 7.2 mg semaglutide.

4. The semaglutide for use according to claim 3, wherein the at least 25% subjects obtaining a body weight reduction of at least 25% is observed after about 72 weeks.

5. The semaglutide for use according to any one of the preceding claims, wherein said administration of semaglutide provides a body weight reduction of at least about 15%.

6. The semaglutide for use according to any one of the preceding claims, wherein said administration of semaglutide provides a body weight reduction of at least 18%.

7. The semaglutide for use according to claim 5 or 6, wherein the body weight reduction of at least about 15% or at least 18% is observed after about 72 weeks.

8. The semaglutide for use according to any one of the preceding claims, wherein said administration of semaglutide provides a reduction of lean body volume compared to total fat volume of less than 20%, such as less than 18%.

9. The semaglutide for use according to claim 8, wherein the reduction of lean body volume compared to total fat volume of less than 20%, such as less than 18%, is observed after about 72 weeks.

10. The semaglutide for use according to any one of the preceding claims, wherein said subcutaneous administration further comprises one or more initial semaglutide dosage

escalation steps of administration of up to about 2.4 mg semaglutide per week, prior to administration of said about 7.2 mg semaglutide per week.

11. The semaglutide for use according to claim 10, wherein said semaglutide is to be administered for at least about 52 weeks, such as about 72 weeks from the initial semaglutide dosage escalation step.

12. The semaglutide for use according to any one of the preceding claims, wherein said semaglutide is to be administered once weekly.

13. The semaglutide for use according to any one of the preceding claims, wherein said semaglutide is to be administered in the form of a pharmaceutical composition comprising semaglutide and said composition has a pH in the range of 5.6 to 9.0.

14. The semaglutide for use according to any one of the preceding claims, wherein said semaglutide is to be administered in the form of a pharmaceutical composition comprising semaglutide and one or more excipients and said composition has a pH in the range of 5.6 to 9.0.

15. The semaglutide for use according to claim 13 or 14, wherein said pharmaceutical composition has a pH of about 7.4.